Streetbeat News

NRXS

NeurAxis, Inc.

Industry

Biotechnology

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Neuraxis reported a decrease in Q3 earnings per share (EPS) from $(1.14) to $(1.35) year-over-year (YoY), and a 22.84% drop in sales from $618.80K to $477.46K YoY.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 10:46 pm

NeurAxis, identified by its ticker NRXS, has successfully raised $3 million in financing by offering preferred stock at a price of $2.38 per share. This capital infusion could be used to fund the company's operations, development, and potential expansion.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:10 pm

NeurAxis (NYSE:NRXS) announced the results of a comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications. The study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The study showed that IB-Stim™ therapy showed improvements in abdominal pain and functional disability compared to baseline, while amitriptyline showed improvements in abdominal pain. IB-Stim™ was more effective than cyproheptadine in improving abdominal pain and did not differ from amitriptyline.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:21 pm

Neuraxis (AMEX:NRXS) reported Q2 losses of $(1.21) per share, a 39.08% decrease YoY. Sales also decreased by 5.36% to $646.00K compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:13 pm

Several stocks experienced significant price movements in Tuesday's mid-day session. Tenon Medical withdrew its proposed public offering, causing its shares to climb 63.5%. Avalo Therapeutics agreed to divest AVTX-800 series, leading to a 52.6% gain. Cognyte Software reported better-than-expected Q2 results and issued FY24 guidance above estimates, resulting in a 24.8% gain. Xos was awarded a contract by the State of California, causing a 23% gain. The Beauty Health Company announced a business transformation program and a $100 million share repurchase, leading to a 16.6% jump. On the other hand, Acelyrin shares fell 60.8% after announcing disappointing trial results. CS Disco shares fell 22.1% after the company announced its CEO's departure.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 5:44 pm

NeurAxis has published a prospective study showing that its product, IB-Stim, improves the quality of life of adolescents with Irritable Bowel Syndrome (IBS).

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:13 pm

NeurAxis Inc (NYSE:NRXS) announced the publication of a study evaluating the efficacy of its IB-Stim technology in treating functional abdominal pain disorders (FAPDs) in adolescents. The study showed significant improvements in patients' quality of life and reductions in abdominal pain, nausea, disability, and anxiety. Despite the positive news, NRXS shares are down 21.1% at $4.10 premarket.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 12:15 pm

NeurAxis (NRXS) has announced the publication of a prospective study showing that its product, IB-Stim, improves the quality of life of adolescents with Irritable Bowel Syndrome (IBS).

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:15 pm

NeurAxis Inc (NYSE:NRXS) is conducting a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-concussion symptoms. The company's President and CEO, Brian Carrico, stated that positive data and FDA clearance could lead to a groundbreaking therapeutic option for post-concussion syndrome. The trial is currently enrolling up to 100 patients and is being conducted at Children's Hospital of Orange County, CA.

Portfolio Pulse from Vandana Singh

August 29, 2023 | 12:54 pm

NeurAxis has highlighted a clinical study on the effect of Auricular Percutaneous Electrical Nerve Field Stimulation in pediatric post-concussion patients. The study is prospective in nature.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 12:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.